Brief: SK Life Science Announces FDA Acceptance For Review Of New Drug Application For Cenobamate Oral Suspension
15/06/2026 16:06
BRIEF-SK Life Science Announces FDA Acceptance For Review Of New Drug Application For Cenobamate Oral Suspension June 15 (Reuters) - SK Biopharmaceuticals Co Ltd 326030.KS:
SK LIFE SCIENCE, INC. ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF NEW DRUG APPLICATION FOR CENOBAMATE ORAL SUSPENSION
Source text: ID:nPn9r4VDBa
Further company coverage: 326030.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SK Biopharmaceuticals
See all newsBrief: Sk Biopharmaceuticals Co Signs Licensing-In Contract With 1St Biotherapeutics
US FDA pauses new enrollment in Biohaven's epilepsy drug trials (updated)
US FDA pauses new enrollment in Biohaven's epilepsy drug trials
Biohaven jumps on SK Biopharma epilepsy licensing deal worth up to $795 million
U.S. STOCKS ON THE MOVE-Meta, Kohl's, J.M. Smucker